During the last session, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s traded shares were 16.0 million, with the beta value of the company hitting 2.16. At the end of the trading day, the stock’s price was $14.63, reflecting an intraday gain of 33.49% or $3.67. The 52-week high for the TNXP share is $1216.00, that puts it down -8211.69 from that peak though still a striking 53.79% gain since the share price plummeted to a 52-week low of $6.76. The company’s market capitalization is $81.79M, and the average trade volume was 1.65 million shares over the past three months.
Tonix Pharmaceuticals Holding Corp (TNXP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. TNXP has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
Tonix Pharmaceuticals Holding Corp (TNXP) registered a 33.49% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 33.49% in intraday trading to $14.63, hitting a weekly high. The stock’s 5-day price performance is 78.85%, and it has moved by -3.81% in 30 days. Based on these gigs, the overall price performance for the year is -98.79%.
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
In the rating firms’ projections, revenue will increase 66.71% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.35M as predicted by 2 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 4.2M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.78M and 2.48M respectively. In this case, analysts expect current quarter sales to shrink by -11.35% and then jump by 69.22% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 79.31%. While earnings are projected to return 95.88% in 2025, the next five years will return 78.59% per annum.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
